Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion type Assertion NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_head.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion wasGeneratedBy ECO_0000203 NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_provenance.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion wasDerivedFrom befree-20150227 NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_provenance.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion SIO_000772 24757092 NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_provenance.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion evidence source_evidence_literature NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_provenance.
- NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_assertion description "[These results indicate that reduction of TNFR2+ T cells in AML postremission phase may result from combined azacitidine/lenalidomide therapy and may contribute to an improved clinical outcome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP748281.RACpmmhRU9ZiWnnB1XbyHHGheJnSPqZwi447eZ9KUntzs130_provenance.